What is this study trying to find out about asthma?

This study is evaluating whether using blood eosinophil counts to guide asthma treatment is better than usual care for managing mild to moderate asthma. Researchers want to see if this biomarker-directed approach reduces asthma attacks and improves symptom control and quality of life. The study is sponsored by the National Healthcare Group Polyclinics to improve asthma care in primary settings.

Who may be eligible for this asthma clinical trial?

Adults aged 21 to 65 with a doctor-diagnosed asthma for at least 4 weeks may be eligible. Participants must not have had recent asthma attacks requiring steroids or hospitalization and must be able to attend study visits over one year. Both men and women can participate. Please review eligibility criteria for more details.

Is there any cost to participate in this asthma clinical trial?

Study-related care, including the study procedures and all trial visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered. Participants can expect to attend appointments approximately every four months during the study.

Actively Recruiting

Phase Not Applicable

Age: 21Years - 65Years

All Genders

ID07486401

Randomized Trial Comparing Blood Eosinophil Guided Treatment to Usual Care for Mild to Moderate Asthma in Primary Care

Led by National Healthcare Group Polyclinics · Updated on 2026-03-20

240

Participants Needed

Research Sites

52 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to compare usual care with biomarker-directed care using blood eosinophil counts for managing patients with mild to moderate asthma in a primary care setting. The goal is to evaluate whether guiding asthma treatment by blood eosinophil count can reduce asthma attacks, improve symptom control, and enhance quality of life compared to standard care. The study is sponsored by the National Healthcare Group Polyclinics and focuses on adults aged 21 to 65 with asthma. Participants are randomly assigned to one of two groups one group receives asthma management guided by blood eosinophil counts biomarker-directed treatment, while the control group receives usual care without the use of this biomarker. Treatment follows the Global Initiative for Asthma GINA 2025 guidelines for mild to moderate asthma steps 1 to 3. The study includes approximately one year of follow-up with visits about every four months. During the study, researchers will monitor the time to the first asthma attack requiring hospitalization, the number of non-hospitalized asthma exacerbations, and worsening of asthma symptoms over 12 months. They will also assess quality of life, asthma control, lung function tests, and healthcare visits related to asthma. Participants must be able to attend scheduled appointments and provide informed consent, with safety and adherence monitored throughout the study period.

CONDITIONS

Brief Title

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

Who Can Participate

Age: 21Years - 65Years

All Genders

Eligibility Criteria

You may qualify if you...

Singaporeans or Singapore Permanent Residents
Patients aged 21 to 65 years old
Physician diagnosed asthma for at least 4 weeks
On or will be started on Global Initiative for Asthma (GINA) 2025 step 1 to 3 treatment
No asthma exacerbations in the 4 weeks before randomisation
Able and willing to attend study appointments approximately every 4 months for 1 year
Able to provide informed consent
Stable cardiovascular status with controlled hypertension and no active heart disease or arrhythmias

You will not qualify if you...

History of life-threatening asthma requiring intubation or intensive care
Severe or difficult to treat asthma
Current use of long-term immunosuppression, Montelukast, Theophylline, or long-term oral steroids
Known causes of eosinophilia other than asthma (e.g., parasitic infection) as judged by physician
Current use of beta-blocking agents including eye-drops
Use of oral, rectal, or parenteral glucocorticoids within 30 days or depot glucocorticoids within 12 weeks prior to recruitment
Diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease, or bronchiectasis
Significant other diseases or disorders that increase risk or affect participation or study results
Current enrollment in another asthma interventional clinical trial
Female participants who are pregnant or planning pregnancy during the study
Planned travel outside the country for 16 or more consecutive weeks during the study
Investigator's assessment of poor ability to follow study instructions or procedures

Research Team

Wern Ee Tang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Randomized Trial Comparing Blood Eosinophil Guided Treatment to Usual Care for Mild to Moderate Asthma in Primary Care

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria